An interventional study of Online program for psoriasis (GAIA-PSO-01) in Psoriasis, sponsored by Gaia AG. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Gaia AG · Not applicable, Interventional, and Treatment
Among 299 studies in Psoriasis with a site in Germany — 13 open to participants now, 30 under way, 15 of them phase 3. Psoriasis · Germany.
Among the 299 studies in Psoriasis with a site in Germany, this one is the 89th largest by enrollment of the 260 interventional ones that give a count, is one of 15 that started in 2023, is one of 7 with no phase, and was the 269th registered.
2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.
This study's enrollment of 348 is above the median of 75 across 1,565 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →13 of the 299 studies in Psoriasis with a site in Germany are open now, in 12 countries. Each count lists the studies.
Of the 174 Psoriasis studies recruiting now, 91 (52%) set no upper age limit and 67 (39%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →299 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 15 started in 2023.
Median enrollment 195 across the 260 interventional studies, 588 across the 39 observational. Of the 264 that completed or were terminated, 160 (61%) have results posted.
274 of 299 have an industry lead sponsor. The 10 most frequent:
Gaia AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Gaia AG has 1 study filed under Psoriasis — fewer than ten, so there is no comparison to draw.
2 of the studies in Psoriasis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013201LEO PharmaA 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis | 2027-06-04 |
| NCT03886246LEO PharmaEffisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study | 2027-09-30 |
Among the 299 studies in Psoriasis with a site in Germany, from their registry updates:
This clinical trial with 348 patients with psoriasis aims to investigate the effectiveness of a self-guided online program for patients with psoriasis.
Patients will be randomized and allocated in a 1:1 ratio to either an intervention group, in which they will receive 12-month-access to an online program for psoriasis in addition to treatment as usual (TAU, n = 174), or to a control group, in which they will receive only TAU (n = 174). TAU is defined as any therapy prescribed or recommended by the GP or specialists (e.g. dermatologist, psychiatrist), which may include topical therapy, phototherapy, pharmacotherapy, psychosocial therapy, etc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants allocated to the intervention group will receive access to an online program for psoriasis (GAIA-PSO-01) in addition to treatment as usual (TAU).
Behavioral: Online program for psoriasis (GAIA-PSO-01)
Participants allocated to the control group will receive access to treatment as usual (TAU).
The program to-be-tested (GAIA-PSO-01) is an interactive online program for independent use by users with psoriasis. It focuses on recognized treatment elements of cognitive behavioral therapy (CBT) and behavior change techniques.
Health-Related Quality of Life
Total score of the Dermatology Life Quality Index (DLQI). Total score ranging from 0-30; higher scores mean a worse outcome.
Time frame: 3 months
Psoriasis Severity
Total score of the Self-Administered Psoriasis Area Severity Index (PASI). Total score ranging from 0-72; higher scores mean a worse outcome.
Time frame: 3 months, 6 months, 12 months
Depressive Symptoms
Total score of the Patient Health Questionnaire (PHQ-9). Total score ranging from 0-27; higher scores mean a worse outcome.
Time frame: 3 months, 6 months, 12 months
Body Surface Area (BSA)
Body Surface Area (BSA) is a measure used to determine the extent of skin involvement in psoriasis. Total score ranging from 0-100; higher scores mean a worse outcome.
Time frame: 3 months, 6 months, 12 months
Health-Related Quality of Life
Total score of the Dermatology Life Quality Index (DLQI). Total score ranging from 0-30; higher scores mean a worse outcome.
Time frame: 6 months, 12 months
Patient Activation
Total score of the Patient Activation Measure-13 (PAM-13). Total score ranging from 0-100; higher scores mean a better outcome.
Time frame: 3 months, 6 months, 12 months
Self-Esteem
Total score of the Rosenberg Self-Esteem Scale (RSE). Total score ranging from 0-30; higher scores mean a better outcome.
Time frame: 3 months, 6 months, 12 months
Body Mass Index
Body mass index (BMI) is a simple measure of body fat based on height and weight. Higher values mean a worse outcome.
Time frame: 3 months, 6 months, 12 months
Alcohol Consumption
Total score of the Alcohol use Disorders Identification Test - Consumption Items (AUDIT-C). Total score ranging from 0-12; higher scores mean a worse outcome.
Time frame: 3 months, 6 months, 12 months
Cigarette Smoking
Cigarette smoking will be assessed with a single question 'How often do you smoke cigarettes?', with response options 'Never/rarely/sometimes/often/very often', coded from 0-4. Higher scores mean a worse outcome.
Time frame: 3 months, 6 months, 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Dec 2024, 15 months.
Of 134 interventional studies with no phase under Psoriasis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gaia AG